




PHARMACEUTICAL 2023

Evelo Biosciences Inc.
Rank 388 of 446





PHARMACEUTICAL 2023

Evelo Biosciences Inc.
Rank 388 of 446

The relative strengths and weaknesses of Evelo Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evelo Biosciences Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 15% points. The greatest weakness of Evelo Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 98% points.

The company's Economic Capital Ratio, given in the ranking table, is -184%, being 227% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	51,573
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,395
Liabilities, Non-Current	57,038
Other Assets	8,026
Other Compr. Net Income	0
Other Expenses	930
Other Liabilities	0
Other Net Income	-5,131
Other Revenues	0
Property and Equipment	4,842
Research and Development	78,554
Selling, General and Administrative Expense	29,912

Output Variable	Value in 1000 USD
Assets	64,441
Liabilities	69,433
Expenses	109,396
Revenues	0
Stockholders Equity	-4,992
Net Income	-114,527
Comprehensive Net Income	-114,527
Economic Capital Ratio	-184%